Carcinoma, Non-Small-Cell Lung

"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.

Descriptor ID	D002289
MeSH Number(s)	C04.588.894.797.520.109.220.249 C08.381.540.140.500 C08.785.520.100.220.500
Concept/Terms	Carcinoma, Non-Small-Cell Lung Carcinoma, Non-Small-Cell Lung Carcinoma, Non Small Cell Lung Carcinomas, Non-Small-Cell Lung Lung Carcinoma, Non-Small-Cell Lung Carcinomas, Non-Small-Cell Non-Small-Cell Lung Carcinomas Nonsmall Cell Lung Cancer Non-Small-Cell Lung Carcinoma Non Small Cell Lung Carcinoma Carcinoma, Non-Small Cell Lung Non-Small Cell Lung Cancer

Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".

Diseases [C]
Neoplasms [C04]
Neoplasms by Site [C04.588]
Thoracic Neoplasms [C04.588.894]
Respiratory Tract Neoplasms [C04.588.894.797]
Lung Neoplasms [C04.588.894.797.520]
Bronchial Neoplasms [C04.588.894.797.520.109]
Carcinoma, Bronchogenic [C04.588.894.797.520.109.220]
Carcinoma, Non-Small-Cell Lung [C04.588.894.797.520.109.220.249]
Respiratory Tract Diseases [C08]
Lung Diseases [C08.381]
Lung Neoplasms [C08.381.540]
Carcinoma, Bronchogenic [C08.381.540.140]
Carcinoma, Non-Small-Cell Lung [C08.381.540.140.500]
Respiratory Tract Neoplasms [C08.785]
Lung Neoplasms [C08.785.520]
Bronchial Neoplasms [C08.785.520.100]
Carcinoma, Bronchogenic [C08.785.520.100.220]
Carcinoma, Non-Small-Cell Lung [C08.785.520.100.220.500]

Below are MeSH descriptors whose meaning is related to "Carcinoma, Non-Small-Cell Lung".

Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in this website by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publications.

Bar chart showing 1978 publications over 30 distinct years, with a maximum of 121 publications in 2020

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1992	11	1	12
1993	11	3	14
1994	16	3	19
1995	18	1	19
1996	20	4	24
1997	16	7	23
1998	18	4	22
1999	25	9	34
2000	42	9	51
2001	28	7	35
2002	34	5	39
2003	46	5	51
2004	53	6	59
2005	56	9	65
2006	56	11	67
2007	66	8	74
2008	70	8	78
2009	72	5	77
2010	71	12	83
2011	96	7	103
2012	91	14	105
2013	107	8	115
2014	91	7	98
2015	98	10	108
2016	90	8	98
2017	90	9	99
2018	104	11	115
2019	98	9	107
2020	113	8	121
2021	59	4	63

Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.

Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, Li J, Chow CW, Mao X, Song X, Lee WC, Wu J, Little L, Gumbs C, Behrens C, Moran C, Weissferdt A, Lee JJ, Sepesi B, Swisher S, Cheng C, Kurie J, Gibbons D, Heymach JV, Wistuba II, Futreal PA, Kalhor N, Zhang J. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun. 2021 12 06; 12(1):7081.

View in: PubMed
Hinterleitner C, Strähle J, Malenke E, Hinterleitner M, Henning M, Seehawer M, Bilich T, Heitmann J, Lutz M, Mattern S, Scheuermann S, Horger M, Maurer S, Walz J, Fend F, Handgretinger R, Seitz C, Weigelin B, Singer S, Salih H, Borst O, Kopp HG, Zender L. Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer. Nat Commun. 2021 12 01; 12(1):7005.

View in: PubMed
Chang JY, Verma V, Feng L, Roth JA. SABR for operable stage I non-small-cell lung cancer: comparison to surgery - Authors' reply. Lancet Oncol. 2021 12; 22(12):e537-e538.

View in: PubMed
Chen M, Chen R, Jin Y, Li J, Hu X, Zhang J, Fujimoto J, Hubert SM, Gay CM, Zhu B, Tian Y, McGranahan N, Lee WC, George J, Hu X, Chen Y, Wu M, Behrens C, Chow CW, Pham HHN, Fukuoka J, Wu J, Parra ER, Little LD, Gumbs C, Song X, Wu CJ, Diao L, Wang Q, Cardnell R, Zhang J, Wang J, Le X, Gibbons DL, Heymach JV, Jack Lee J, William WN, Cheng C, Glisson B, Wistuba I, Andrew Futreal P, Thomas RK, Reuben A, Byers LA, Zhang J. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun. 2021 11 17; 12(1):6655.

View in: PubMed
Malek AE, Khalil M, Hachem R, Chaftari AM, Fares J, Jiang Y, Kontoyiannis DP, Fossella F, Chaftari P, Mulanovich VE, Viola GM, Raad II. Impact of Checkpoint Inhibitor Immunotherapy, Primarily Pembrolizumab, on Infection Risk in Patients With Advanced Lung Cancer: A Comparative Retrospective Cohort Study. Clin Infect Dis. 2021 11 02; 73(9):e2697-e2704.

View in: PubMed
Ramagopalan S, Gupta A, Arora P, Thorlund K, Ray J, Subbiah V. Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer. JAMA Netw Open. 2021 11 01; 4(11):e2134299.

View in: PubMed
Wu L, Zhu J, Rudqvist NP, Welsh J, Lee P, Liao Z, Xu T, Jiang M, Zhu X, Pan X, Li P, Zhou Z, He X, Yin R, Feng J. T-Cell Receptor Profiling and Prognosis After Stereotactic Body Radiation Therapy For Stage I Non-Small-Cell Lung Cancer. Front Immunol. 2021; 12:719285.

View in: PubMed
Shang S, Liu J, Verma V, Wu M, Welsh J, Yu J, Chen D. Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates. Cancer Commun (Lond). 2021 11; 41(11):1086-1099.

View in: PubMed
Shojaee S, Roy-Chowdhuri S, Safi J, Grosu HB. Cytologic Investigations for the Diagnosis of Malignant Pleural Effusion in Non-small Cell Lung Cancer: State-of-the-art Review for Pulmonologists. J Bronchology Interv Pulmonol. 2021 Oct 01; 28(4):310-321.

View in: PubMed
Wilkinson S, Gupta A, Scheuer N, Mackay E, Arora P, Thorlund K, Wasiak R, Ray J, Ramagopalan S, Subbiah V. Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data. JAMA Netw Open. 2021 10 01; 4(10):e2126306.

View in: PubMed

People

Explore

Similar Concepts

Top Journals